Active Learning‐Assisted Exploration of [PO 40 Mo 12 ] 3− for Alzheimer's Therapy Insights
Source abstract
Abstract
Abstract Alzheimer's disease (AD), involving amyloid‐β (Aβ) aggregation, has potential therapeutic modulators in polyoxometalates (POMs) like [PMo 12 O 40 ] 3− . To clarify their inhibitory mechanisms, a multiscale computational strategy integrating active‐learning Bayesian Optimization (BO) and density functional theory (DFT) is employed to explore low‐energy configurations of isolated amino acids, [PMo 12 O 40 ] 3 − –amino acid complexes, and [PMo 12 O 40 ] 3 − –peptide systems. Hydrogen bonding and Coulombic repulsion dominate adsorption stability. Crucially, oxygen atoms in the [PMo 12 O 40 ] 3 − cluster form multiple weak interactions (e.g., van der Waals, hydrophobic) with alkyl side‐chain hydrogens in Aβ peptides. The synergistic effect of these weak interactions induces robust binding between the POM and peptide chains, stabilizing a tightly bound complex that sterically hinders Aβ self‐assembly. Notably, simulations predict that the cluster preferentially targets hydrophobic amino acids with alkyl chains (valine, lysine, leucine, isoleucine) located in Aβ regions critical for aggregation—specifically, namely Aβ12, Aβ16‐18, Aβ24, Aβ28, Aβ31‐32, Aβ34‐36, and Aβ39‐41. These insights highlight the role of multivalent weak interactions in POM‐mediated inhibition and identify key interfacial residues for therapeutic targeting.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Polyoxometalates: Synthesis and Applications · Nanocluster Synthesis and Applications · Alzheimer's disease research and treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Functional Molecular Solids Ministry of Education College of Chemistry and Materials Science Anhui Normal University Wuhu Anhui 241002 P.R. China
Funding
National Natural Science Foundation of China
References (29)
Show source-provided references
1. 10.1038/d41586-018-05718-510.1038/d41586-018-05718-5 ↗
2. 10.1007/978-981-32-9358-8_1610.1007/978-981-32-9358-8_16 ↗
3. 10.1038/s41593-020-0687-610.1038/s41593-020-0687-6 ↗
4. 10.1038/s41573-022-00391-w10.1038/s41573-022-00391-w ↗
5. 10.1007/s40265-023-01858-910.1007/s40265-023-01858-9 ↗
6. 10.1002/anie.20100706710.1002/anie.201007067 ↗
7. 10.1002/anie.20231970010.1002/anie.202319700 ↗
8. 10.1515/revic-2023-000810.1515/revic-2023-0008 ↗
9. 10.1002/anie.20180386810.1002/anie.201803868 ↗
10. 10.1002/cnma.20190005710.1002/cnma.201900057 ↗
11. 10.1016/j.colsurfa.2010.11.06810.1016/j.colsurfa.2010.11.068 ↗
12. 10.1039/D1CC05792H10.1039/D1CC05792H ↗
13. 10.1093/nsr/nwae22610.1093/nsr/nwae226 ↗
14. 10.1186/s40478-023-01694-810.1186/s40478-023-01694-8 ↗
15. 10.1126/science.abm728510.1126/science.abm7285 ↗
16. 10.1103/PhysRev.140.A113310.1103/PhysRev.140.A1133 ↗
17. 10.1017/CBO978051180576910.1017/CBO9780511805769 ↗
18. Parr R. G. · 1989
19. 10.1103/PhysRev.136.B86410.1103/PhysRev.136.B864 ↗
20. Jing B. · Adv. Neural Inf. Process. Syst. · 2022 · 35
21. 10.1021/ja00112a02210.1021/ja00112a022 ↗
22. 10.1021/acs.jctc.2c0029010.1021/acs.jctc.2c00290 ↗
23. 10.1021/acs.jcim.5b0024310.1021/acs.jcim.5b00243 ↗
24. 10.1021/ci600564610.1021/ci6005646 ↗
25. 10.1021/ct900005c10.1021/ct900005c ↗
26. 10.1038/s41524-019-0175-210.1038/s41524-019-0175-2 ↗
27. CEST Group Bayesian Optimization Structure Search (BOSS) (accessed: August 2025) https://gitlab.com/cest‐group/boss.
28. 10.1021/acs.jcim.2c0112010.1021/acs.jcim.2c01120 ↗
29. 10.1021/acs.jctc.0c0064810.1021/acs.jctc.0c00648 ↗